Cogent Biosciences, Inc. Income Statement
COGT / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| SG&A Expense | $63.6M | $43.3M | $34.4M | $26.2M | $19.6M | $17.4M | $11.0M | $7.5M | $4.7M |
| R&D Expense | $269.8M | $232.7M | $173.8M | $121.6M | $55.9M | $25.7M | $43.7M | $38.3M | $29.8M |
| Operating Income | -$333.4M | -$275.9M | -$208.1M | -$147.8M | -$75.6M | -$82.2M | -$32.2M | -$36.0M | -$26.2M |
| Income Tax | $0 | - | - | - | - | - | - | - | - |
| Net Income | -$328.9M | -$255.9M | -$192.4M | -$140.2M | -$72.3M | -$74.8M | -$31.8M | -$34.5M | -$25.5M |
| EPS (Basic) | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | - | - | - | - |
| EPS (Diluted) | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | - | - | - | - |
| Shares Outstanding | 128.9M | 103.9M | 79.7M | 58.7M | 38.7M | 11.1M | 7.6M | 24.9M | 10.2M |